Table 2.
Measured amikacin concentration ranges, reported as the difference between maximum and minimum observed values with relative IQR (mg/L), together with prediction error metrics AFE and MAE (mg/L)
| (a) AMICREA-CI cohort | ||||
|---|---|---|---|---|
| GA (wk) | Co-administrations | Amikacin range (mg/L) | AFE | MAE (mg/L) |
| <32 | None | 71.6 (53.6–89.6) | 1.05 | 7.57 |
| Ino only | 61.1 (48.9–73.4) | 0.91 | 4.49 | |
| Ibu only | 42.9 (27.1–58.8) | 1.14 | 5.44 | |
| Both | 70.0 (55.2–84.8) | 0.91 | 3.57 | |
| 32–37 | None | 60.1 (43.5–76.7) | 0.98 | 8.62 |
| Ino only | 46.4 (31.9–60.9) | 0.87 | 6.69 | |
| Ibu only | 39.0 (23.4–54.6) | 1.02 | 8.08 | |
| Both | 37.0 (18.5–55.5) | 1.32 | 8.32 | |
| >37 | None | 49.1 (33.9–64.3) | 0.92 | 7.62 |
| Ino only | 53.2 (41.7–64.7) | 0.98 | 5.36 | |
| Ibu only | 37.5 (21.3–53.7) | 1.02 | 7.59 |
| (b) AMICREA-TH cohort | ||||
|---|---|---|---|---|
| GA (wk) | TH | Amikacin range (mg/L) | AFE | MAE (mg/L) |
| 32–37 | No | 9.7 (6.1–13.3) | 0.46 | 5.86 |
| Yes | 18.9 (15.2–22.6) | 0.43 | 5.31 | |
| > 37 | No | 26.5 (18.2–34.8) | 0.51 | 5.54 |
| Yes | 37.0 (32.8–41.2) | 0.66 | 3.96 |
a: Stratification by GA and concomitant inotrope and/or ibuprofen administration in the AMICREA-CI cohort. b: Stratification by GA and TH in the AMICREA-TH cohort.